News Sanofi to lay off 229 Blueprint employees, close offices A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.